Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free CTX Stock Alerts

Crescita Therapeutics (CTX) Competitors

Crescita Therapeutics logo
C$0.75 0.00 (0.00%)
As of 05/22/2026 09:30 AM Eastern
Compare

CTX vs. HEXO, VIR, ZOM, LABS, and META

Should you buy Crescita Therapeutics stock or one of its competitors? MarketBeat compares Crescita Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crescita Therapeutics include HEXO (HEXO), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), MediPharm Labs (LABS), and Meta Growth (META). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Crescita Therapeutics compare to HEXO?

Crescita Therapeutics (TSE:CTX) and HEXO (TSE:HEXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Crescita Therapeutics has a beta of -1.339634, meaning that its share price is 234% less volatile than the broader market. Comparatively, HEXO has a beta of 2.13, meaning that its share price is 113% more volatile than the broader market.

In the previous week, Crescita Therapeutics had 1 more articles in the media than HEXO. MarketBeat recorded 1 mentions for Crescita Therapeutics and 0 mentions for HEXO. Crescita Therapeutics' average media sentiment score of 1.74 beat HEXO's score of 0.00 indicating that Crescita Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Crescita Therapeutics Very Positive
HEXO Neutral

Crescita Therapeutics has higher earnings, but lower revenue than HEXO. Crescita Therapeutics is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$23.22M0.60-C$2.61M-C$0.01N/A
HEXOC$124.10M0.00-C$273.18M-C$3.41N/A

Crescita Therapeutics has a net margin of -1.38% compared to HEXO's net margin of -220.13%. Crescita Therapeutics' return on equity of -2.07% beat HEXO's return on equity.

Company Net Margins Return on Equity Return on Assets
Crescita Therapeutics-1.38% -2.07% -8.26%
HEXO -220.13%-106.39%-14.96%

3.1% of Crescita Therapeutics shares are held by institutional investors. Comparatively, 7.6% of HEXO shares are held by institutional investors. 10.9% of Crescita Therapeutics shares are held by insiders. Comparatively, 3.0% of HEXO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Crescita Therapeutics beats HEXO on 8 of the 12 factors compared between the two stocks.

How does Crescita Therapeutics compare to Viridium Pacific Group?

Crescita Therapeutics (TSE:CTX) and Viridium Pacific Group (CVE:VIR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

3.1% of Crescita Therapeutics shares are held by institutional investors. 10.9% of Crescita Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Crescita Therapeutics had 1 more articles in the media than Viridium Pacific Group. MarketBeat recorded 1 mentions for Crescita Therapeutics and 0 mentions for Viridium Pacific Group. Crescita Therapeutics' average media sentiment score of 1.74 beat Viridium Pacific Group's score of 0.00 indicating that Crescita Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Crescita Therapeutics Very Positive
Viridium Pacific Group Neutral

Crescita Therapeutics has higher revenue and earnings than Viridium Pacific Group. Crescita Therapeutics is trading at a lower price-to-earnings ratio than Viridium Pacific Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$23.22M0.60-C$2.61M-C$0.01N/A
Viridium Pacific GroupC$1.09M34.46-C$12.64M-C$0.13N/A

Viridium Pacific Group has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -1.38%. Viridium Pacific Group's return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Crescita Therapeutics-1.38% -2.07% -8.26%
Viridium Pacific Group N/A N/A N/A

Summary

Crescita Therapeutics beats Viridium Pacific Group on 7 of the 12 factors compared between the two stocks.

How does Crescita Therapeutics compare to Zomedica Pharmaceuticals Corp. (ZOM.V)?

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

3.1% of Crescita Therapeutics shares are owned by institutional investors. 10.9% of Crescita Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zomedica Pharmaceuticals Corp. (ZOM.V) has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -1.38%. Zomedica Pharmaceuticals Corp. (ZOM.V)'s return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zomedica Pharmaceuticals Corp. (ZOM.V)N/A N/A N/A
Crescita Therapeutics -1.38%-2.07%-8.26%

Zomedica Pharmaceuticals Corp. (ZOM.V) has higher earnings, but lower revenue than Crescita Therapeutics. Crescita Therapeutics is trading at a lower price-to-earnings ratio than Zomedica Pharmaceuticals Corp. (ZOM.V), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A-C$0.11N/A
Crescita TherapeuticsC$23.22M0.60-C$2.61M-C$0.01N/A

In the previous week, Crescita Therapeutics had 1 more articles in the media than Zomedica Pharmaceuticals Corp. (ZOM.V). MarketBeat recorded 1 mentions for Crescita Therapeutics and 0 mentions for Zomedica Pharmaceuticals Corp. (ZOM.V). Crescita Therapeutics' average media sentiment score of 1.74 beat Zomedica Pharmaceuticals Corp. (ZOM.V)'s score of 0.00 indicating that Crescita Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Zomedica Pharmaceuticals Corp. (ZOM.V) Neutral
Crescita Therapeutics Very Positive

Summary

Crescita Therapeutics beats Zomedica Pharmaceuticals Corp. (ZOM.V) on 6 of the 10 factors compared between the two stocks.

How does Crescita Therapeutics compare to MediPharm Labs?

MediPharm Labs (TSE:LABS) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Crescita Therapeutics has a net margin of -1.38% compared to MediPharm Labs' net margin of -20.21%. Crescita Therapeutics' return on equity of -2.07% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
MediPharm Labs-20.21% -23.55% -7.17%
Crescita Therapeutics -1.38%-2.07%-8.26%

Crescita Therapeutics has lower revenue, but higher earnings than MediPharm Labs. Crescita Therapeutics is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$45.12M0.75-C$12.05M-C$0.02N/A
Crescita TherapeuticsC$23.22M0.60-C$2.61M-C$0.01N/A

In the previous week, MediPharm Labs and MediPharm Labs both had 1 articles in the media. Crescita Therapeutics' average media sentiment score of 1.74 beat MediPharm Labs' score of 0.00 indicating that Crescita Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MediPharm Labs
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Crescita Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

0.3% of MediPharm Labs shares are held by institutional investors. Comparatively, 3.1% of Crescita Therapeutics shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by company insiders. Comparatively, 10.9% of Crescita Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MediPharm Labs has a beta of -0.448907, suggesting that its stock price is 145% less volatile than the broader market. Comparatively, Crescita Therapeutics has a beta of -1.339634, suggesting that its stock price is 234% less volatile than the broader market.

Summary

Crescita Therapeutics beats MediPharm Labs on 7 of the 12 factors compared between the two stocks.

How does Crescita Therapeutics compare to Meta Growth?

Crescita Therapeutics (TSE:CTX) and Meta Growth (CVE:META) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Meta Growth has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -1.38%. Meta Growth's return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Crescita Therapeutics-1.38% -2.07% -8.26%
Meta Growth N/A N/A N/A

3.1% of Crescita Therapeutics shares are owned by institutional investors. 10.9% of Crescita Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Meta Growth had 7 more articles in the media than Crescita Therapeutics. MarketBeat recorded 8 mentions for Meta Growth and 1 mentions for Crescita Therapeutics. Crescita Therapeutics' average media sentiment score of 1.74 beat Meta Growth's score of 0.12 indicating that Crescita Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Crescita Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Meta Growth
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Crescita Therapeutics has higher earnings, but lower revenue than Meta Growth. Crescita Therapeutics is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$23.22M0.60-C$2.61M-C$0.01N/A
Meta GrowthC$60.96M0.54-C$50.41M-C$0.21N/A

Summary

Crescita Therapeutics and Meta Growth tied by winning 6 of the 12 factors compared between the two stocks.

Get Crescita Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTX vs. The Competition

Export
MetricCrescita TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$13.96MC$2.25BC$6.46BC$12.16B
Dividend YieldN/A2.95%2.76%6.20%
P/E Ratio-75.005.1621.2137.64
Price / Sales0.601,770.59554.3811.68
Price / Cash1.2010.1843.4982.29
Price / Book0.9710.6110.374.50
Net Income-C$2.61MC$20.70BC$3.57BC$299.09M
7 Day Performance-1.32%8.21%6.40%2.48%
1 Month PerformanceN/A3.75%3.53%1.47%
1 Year Performance38.89%22.83%34.04%53.55%

Crescita Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTX
Crescita Therapeutics
N/AC$0.75
flat		N/A+38.9%C$13.96MC$23.22MN/A62
HEXO
HEXO
N/AN/AN/AN/AC$38.72MC$124.10MN/A690
VIR
Viridium Pacific Group
N/AC$0.38
+5.6%		N/A+0.0%C$37.52MC$1.09MN/A580
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
N/AC$0.29
-6.6%		N/A+0.0%C$36.73MN/AN/A50
LABS
MediPharm Labs
N/AC$0.08
flat		N/A+6.7%C$33.99MC$45.12MN/A130

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CTX) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel